Standout Papers

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced... 2014 2026 2018 2022 1.6k
  1. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial (2014)
    Yi‐Long Wu, Caicun Zhou et al. The Lancet Oncology

Immediate Impact

4 by Nobel laureates 5 from Science/Nature 80 standout
Sub-graph 1 of 19

Citing Papers

Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations
2023 Standout
4 intermediate papers

Works of Miyoung Kim being referenced

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
2014 Standout

Author Peers

Author Last Decade Papers Cites
Miyoung Kim 962 2047 235 1552 184 4.0k
Eeva Salminen 998 1380 98 1108 136 4.2k
Renzo Boldorini 880 901 156 1726 242 5.1k
Yan Li 1411 997 84 1496 201 4.3k
Vincenzo Arena 1077 1019 173 938 265 5.0k
Toshio Shimizu 2266 1076 76 1492 285 5.2k
Lei Huang 1801 870 63 1337 150 4.5k
Tomonobu Koizumi 1126 1887 87 854 297 5.0k
Francesco Giuliani 602 1227 40 2100 160 4.0k
Tetsuji Takayama 2259 1053 488 1639 264 6.0k
Michael Bitzer 1507 1380 150 1230 196 5.4k

All Works

Loading papers...

Rankless by CCL
2026